Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia
Current Oncology · 27.10.2023 · 30 (11) · 9501-9513
DOI: 10.3390/curroncol30110688 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 27.10.2023. Verfasst von Rushi Shah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Sarcopenia, Ovarian Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single institution were analyzed. Patients with a skeletal muscle index less than 39 cm2/m2 measured on a CT scan were considered sarcopenic. Sarcopenic and non-sarcopenic patients were compared with regard to relative dose intensity (RDI), completion of scheduled chemotherapy, toxicity, and survival. A total of 62 (35.8%) women were sarcopenic. Sarcopenic women were less likely to complete at least six cycles of chemotherapy (83.9% vs. 95.5%, p = 0.02). The mean RDI for both carboplatin (80.4% vs. 89.4%, p = 0.03) and paclitaxel (91.9% vs. 104.1%, p = 0.03) was lower in sarcopenic patients compared to non-sarcopenic patients. Despite these differences in chemotherapy, there was no difference in neutropenia or median overall survival (3.99 vs. 4.57 years, p = 0.62) between the sarcopenic and non-sarcopenic women, respectively. This study highlights the importance of considering lean body mass instead of body weight or surface area in chemotherapy dosing formulas for sarcopenic women with advanced EOC. Further research is needed to optimize chemotherapy strategies based on individual body composition, potentially leading to improved dosing strategies in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Gynecologic Oncology, Summa Health, Akron, OH 44304, USA.
- Department of Quantitative Health Sciences, Division Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA.
- Department of Obstetrics and Gynecology, Division of Gynecological Surgery, Mayo Clinic, Rochester, MN 55905, USA.
ORCID-Profile: Amanika Kumar
Förderung
- NCI NIH HHS
Zitieren
APA
Shah, R., Polen-De, C., McGree, M., Fought, A., & Kumar, A. (2023). Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia. Current Oncology, 30(11), 9501-9513. https://doi.org/10.3390/curroncol30110688
Vancouver
Shah R, Polen-De C, McGree M, Fought A, Kumar A. Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia. Current Oncology. 2023;30(11):9501-9513. doi:10.3390/curroncol30110688
BibTeX
@article{Shah2023,
author = {Shah, Rushi and Polen-De, Clarissa and McGree, Michaela and Fought, Angela and Kumar, Amanika},
title = {Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia},
journal = {Current Oncology},
year = {2023},
volume = {30},
number = {11},
pages = {9501--9513},
doi = {10.3390/curroncol30110688}
}
EUVIMED